Fig. 6. AEs leading to trial product discontinuation for baseline BMI class (<30 kg m⁻², 30 to <35 kg m⁻², 35 to <40 kg m⁻², and ≥40 kg m⁻²); cumulative incidence for first event over time (left) and cumulative mean number of events over time (right).

Data are in-trial from the full analysis set. sema, semaglutide.